Canaccord Genuity Maintains Buy on 10x Genomics, Lowers Price Target to $20
Portfolio Pulse from Benzinga Newsdesk
Canaccord Genuity has maintained a Buy rating on 10x Genomics but lowered the price target from $32 to $20, indicating a more cautious outlook.

October 10, 2024 | 3:33 pm
News sentiment analysis
Sort by:
Ascending
NEUTRAL IMPACT
Canaccord Genuity has maintained a Buy rating on 10x Genomics but lowered the price target from $32 to $20, indicating a more cautious outlook.
The maintenance of a Buy rating suggests continued confidence in the company's prospects, but the lowered price target reflects a more cautious stance, possibly due to market conditions or company performance. This mixed signal may result in a neutral short-term impact on the stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100